Telisotuzumab vedotin

View Clinical trials for Telisotuzumab vedotin Get Telisotuzumab vedotin Patent Info for Free

Inn NameTelisotuzumab vedotin
Lab CodesABBV-399, ABT-700-vcMMAE
Chemical NameImmunoglobulin G1-kappa, anti-[Homo sapiens MET (met proto-oncogene, hepatocyte growth factor (HGF) receptor, HGFR, scatter factor (SF) receptor, HGF/SF receptor, receptor tyrosine-protein kinase c-met, papillary renal cell carcinoma 2, RCCP2)], humanized monoclonal antibody conjugated to auristatin E; gamma1 heavy chain (1-445) [humanized VH (Homo sapiens IGHV1-2*02 (92.90%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -Homo sapiens IGHG1*03, G1m3 (CH1 (119-216), hinge K7>del, T8>C (223), T10>del (217-229), CH2 (230- 339), CH3 (340-444), CHS K>del (445)) (119-445)], (221- 218')-disulfide with kappa light chain (1’-218’) [humanized V-KAPPA (Homo sapiens IGKV4-1*01 (85.10%) - IGKJ4*01) [10.3.9] (1'-111') -Homo sapiens IGKC*01, Km3 (112'-218')]; dimer (223-223":225-225":228:228")- trisdisulfide; conjugated, on an average of 3 cysteinyl, to monomethylauristatin E (MMAE), via a cleavablemaleimidocaproyl-valyl-citrullinylp-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker (For the vedotin part, please refer to the document “INN for pharmaceutical substances: Names for radicals, groups and others”)
SequenceHeavy chain
QVQLVQSGAE VKKPGASVKV SCKASGYIFT AYTMHWVRQA PGQGLEWMGW 50
IKPNNGLANY AQKFQGRVTM TRDTSISTAY MELSRLRSDD TAVYYCARSE 100
ITTEFDYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKRVEPKS CDCHCPPCPA PELLGGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL 350
PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400
GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPG 445

Light chain
DIVMTQSPDS LAVSLGERAT INCKSSESVD SYANSFLHWY QQKPGQPPKL 50
LIYRASTRES GVPDRFSGSG SGTDFTLTIS SLQAEDVAVY YCQQSKEDPL 100
TFGGGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC 218

Disulfide bridges location
Intra-H (C23-C104) 22-96 145-201 260-320 366-424
22''-96'' 145''-201'' 260''-320'' 366''-424''
Intra-L (C23-C104) 23'-92' 138'-198'
23'''-92''' 138'''-198'''
Inter-H-L (h 5-CL 126)* 221-218' 221''-218'''
Inter-H-H (h 11, h 14)* 225-225'' 228-228'' (h 8>C) 223-223''
*Two or three of the inter-chain disulfide bridges are not present, an average of 3 cysteinyl being conjugated
each via a thioether bond to a drug linker.

N-glycosylation sites
H CH2 N84.4:
296, 296''
Fucosylated complex bi-antennary CHO-type glycans
Chemical StructureTelisotuzumab vedotin.png
Cas Registry Number1714088-51-3
New Molecular EntityYes
OriginatorAbbVie
Mechanism Of Actionc-Met receptor tyrosine kinase (c-MET) (MET) (HGFR) (c-Met proto-oncogene) inhibitor
Who Atc CodesL01X (Other Antineoplastic Agents)
Ephmra CodesL1X (All Other Antineoplastics)
IndicationSolid tumors

Free counters!